{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T13:08:07Z","timestamp":1779455287679,"version":"3.53.1"},"reference-count":25,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Hepatitis B core-related antigen (HBcrAg) is a surrogate marker that reflects the transcriptional activity of covalently closed circular DNA (cccDNA). However, the impact of switching nucleos(t)ide analogs on HBcrAg levels remains unclear. The current study evaluated changes in HBcrAg levels following a switch from entecavir (ETV) to tenofovir alafenamide (TAF) compared with continued ETV therapy. Methods: This retrospective study included patients with chronic hepatitis B who either switched from ETV to TAF between 2017 and 2022 (ETV\u2013TAF group) or continued ETV therapy during the same period (ETV group). HBcrAg levels were measured annually, and longitudinal changes over 3 years were analyzed based on an index year defined for each patient. Propensity score matching for age, sex, HBcrAg levels, liver transplantation status, and ETV treatment duration yielded 10 patients per group. Results: Baseline characteristics were well balanced after matching. HBV DNA and HBsAg levels remained suppressed in both groups throughout follow-up. The ETV-TAF group showed greater declines in HBcrAg than the ETV group at year 2 (\u22120.20 vs. \u22120.10 log U\/mL, p = 0.007) and year 3 (\u22120.30 vs. \u22120.10 log U\/mL, p = 0.006). No virological breakthroughs occurred. Conclusions: Switching from ETV to TAF was associated with greater reductions in HBcrAg levels over 3 years than continued ETV therapy, even in patients with suppressed HBV DNA. These findings suggest that switching to TAF may be associated with further suppression of viral transcriptional activity reflected by HBcrAg reduction and support its potential clinical utility for achieving deeper viral suppression.<\/jats:p>","DOI":"10.3390\/jcm15114021","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:14:52Z","timestamp":1779452092000},"page":"4021","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Greater Reductions in Hepatitis B Core-Related Antigen Associated with Switching from Entecavir to Tenofovir Alafenamide Compared with Continued Entecavir Therapy: A Retrospective Observational Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8594-0066","authenticated-orcid":false,"given":"Masanori","family":"Fukushima","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2639-7299","authenticated-orcid":false,"given":"Satoshi","family":"Miuma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9353-2780","authenticated-orcid":false,"given":"Yasuhiko","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0001-7377","authenticated-orcid":false,"given":"Ryu","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Haraguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisamitsu","family":"Miyaaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rizzo, G.E.M., Cabibbo, G., and Crax\u00ec, A. (2022). Hepatitis B virus-associated hepatocellular carcinoma. Viruses, 14.","DOI":"10.3390\/v14050986"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5009\/gnl18546","article-title":"Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis","volume":"14","author":"Wang","year":"2020","journal-title":"Gut Liver"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Drafting Committee for Hepatitis Management Guidelines, and Japan Society of Hepatology (2014). JSH guidelines for the management of hepatitis B virus infection. Hepatol. Res., 44, 1\u201358.","DOI":"10.1111\/hepr.12269"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13021","DOI":"10.1038\/s41598-020-69522-w","article-title":"Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score","volume":"10","author":"Kaneko","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/jvh.12688","article-title":"Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy","volume":"24","author":"Cheung","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1111\/jgh.15563","article-title":"Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"36","author":"Kaneko","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/infdis\/jiv572","article-title":"Hepatitis B virus (HBV) core-related antigen during Nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma","volume":"213","author":"Honda","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/jgh.16558","article-title":"Role of hepatitis B core-related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta-analysis","volume":"39","author":"Cao","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3350\/cmh.2022.0434","article-title":"Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy","volume":"29","author":"Inoue","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MEG.0000000000001733","article-title":"Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels","volume":"32","author":"Kumada","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Uchida, Y., Nakao, M., Yamada, S., Tsuji, S., Uemura, H., Kouyama, J.I., Naiki, K., Sugawara, K., Nakayama, N., and Imai, Y. (2022). Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0262764"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Drafting Committee for Hepatitis Management Guidelines, and Japan Society of Hepatology (2020). Japan Society of Hepatology Guidelines for the Management of hepatitis B virus Infection: 2019 update. Hepatol. Res., 50, 892\u2013923.","DOI":"10.1111\/hepr.13504"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cgh.2020.04.045","article-title":"Hepatitis B core-related antigen to indicate high viral load: Systematic review and meta-analysis of 10,397 individual participants","volume":"19","author":"Yoshida","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"98658","DOI":"10.4254\/wjh.v17.i1.98658","article-title":"Hepatitis B core-related antigen as a promising serological marker for monitoring hepatitis B virus cure","volume":"17","author":"Qiu","year":"2025","journal-title":"World J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jgh3.12443","article-title":"Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B","volume":"5","author":"Itokawa","year":"2021","journal-title":"JGH Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/jmv.25644","article-title":"Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate","volume":"92","author":"Uchida","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/jmv.25515","article-title":"Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B","volume":"91","author":"Hagiwara","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Tajiri, K., Hayashi, Y., Murayama, A., Muraishi, N., Minemura, M., and Yasuda, I. (2024). Decrease in HBsAg after TAF switching from entecavir during long-term treatment of chronic hepatitis B virus infection. Viruses, 17.","DOI":"10.3390\/v17010044"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.14309\/ajg.0000000000001157","article-title":"Outcomes of sequential therapy with tenofovir alafenamide after long-term entecavir","volume":"116","author":"Nguyen","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.14482","article-title":"Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B","volume":"40","author":"Ogawa","year":"2020","journal-title":"Liver Int."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4021\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T12:35:53Z","timestamp":1779453353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15114021"],"URL":"https:\/\/doi.org\/10.3390\/jcm15114021","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}